MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco-26-00327

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.

Beaufils Audrey, De Martino Julien, Jiang Xiaofeng, Blanchard Théau, Fraunhoffer Nicolas, Mendes Diana, Pignolet Camille, Bourega Taib, Meneghetti Asier Rabasco, Sainath Srividhya, Albuquerque Miguel, Colnot Nathalie, Tihy Matthieu, Turpin Anthony, Ben Abdelghani Meher, Wei Alice, Mitry Emmanuel, Lecomte Thierry, Biagi James, Artru Pascal, Evesque Ludovic, Lambert Aurélien, Renouf Daniel J, Mauduit Marjorie, Dusetti Nelson J, Hammel Pascal, Conroy Thierry, Bachet Jean-Baptiste, de Mestier Louis, Rebours Vinciane, Cros Jérôme, Kather Jakob Nikolas, Nicolle Rémy

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: The choice of adjuvant chemotherapy in pancreatic ductal adenocarcinoma (PDAC) is mainly guided by patients' general condition. We hypothesized that tumor morphology may predict differential treatment benefit and tested whether deep learning applied to histology images could derive a biomarker of relative benefit from gemcitabine (GEM) versus modified FOLFIRINOX (mFOLFIRINOX) in resected PDAC.

PATIENTS AND

METHODS

Standard whole-slide images from a retrospective multicentric series of 231 patients who underwent curative-intent pancreatectomy and received adjuvant mFOLFIRINOX (n = 54) or GEM (n = 177) were used to train regimen-specific histology models on disease-free survival (DFS), which were then combined into PANCprAId, a biomarker estimating personalized relative benefit from adjuvant GEM versus mFOLFIRINOX. External validation was performed in the randomized PRODIGE-24/CCTG PA6 trial (n = 313).

RESULTS

In PRODIGE-24/CCTG PA6, the treatment-specific histology scores used to construct PANCprAId stratified outcomes among patients treated with GEM (hazard ratio [HR], 1.69 [95% CI, 1.04 to 2.73]; P = .03) and mFOLFIRINOX (HR, 2.02 [95% CI, 1.4 to 3.0]; P < .001). When combined into PANCprAId, the biomarker identified subgroups with differential relative benefit from adjuvant GEM versus mFOLFIRINOX, with significant treatment interactions for DFS (interaction P = .003) and cancer-specific survival (interaction P = .001). Predicted sensitivity to each regimen was associated with distinct epithelial and stromal features.

CONCLUSION

Histology-based deep learning can derive a predictive biomarker of relative benefit from adjuvant GEM versus mFOLFIRINOX in resected PDAC.

Для цитирования: Beaufils Audrey, De Martino Julien, Jiang Xiaofeng, Blanchard Théau, Fraunhoffer Nicolas, Mendes Diana, Pignolet Camille, Bourega Taib, Meneghetti Asier Rabasco, Sainath Srividhya, Albuquerque Miguel, Colnot Nathalie, Tihy Matthieu, Turpin Anthony, Ben Abdelghani Meher, Wei Alice, Mitry Emmanuel, Lecomte Thierry, Biagi James, Artru Pascal, Evesque Ludovic, Lambert Aurélien, Renouf Daniel J, Mauduit Marjorie, Dusetti Nelson J, Hammel Pascal, Conroy Thierry, Bachet Jean-Baptiste, de Mestier Louis, Rebours Vinciane, Cros Jérôme, Kather Jakob Nikolas, Nicolle Rémy. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. DOI: 10.1200/jco-26-00327.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.